JP4758984B2 - 抗ｃｓ１抗体の治療的使用 - Google Patents

抗ｃｓ１抗体の治療的使用 Download PDF

Info

Publication number
JP4758984B2
JP4758984B2 JP2007506135A JP2007506135A JP4758984B2 JP 4758984 B2 JP4758984 B2 JP 4758984B2 JP 2007506135 A JP2007506135 A JP 2007506135A JP 2007506135 A JP2007506135 A JP 2007506135A JP 4758984 B2 JP4758984 B2 JP 4758984B2
Authority
JP
Japan
Prior art keywords
antibody
cells
antibodies
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007506135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530675A (ja
JP2007530675A5 (enrdf_load_stackoverflow
Inventor
マーナ ウィリアムズ，
ジェイ． ユン ツォ，
ニコラス エフ． ランドルフィー，
デイビッド ビー． パワーズ，
ロバート ビー． ダブリッジ，
デビー ロウ，
ガオ リュー，
Original Assignee
アボット バイオセラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by アボット バイオセラピューティクス コーポレイション filed Critical アボット バイオセラピューティクス コーポレイション
Publication of JP2007530675A publication Critical patent/JP2007530675A/ja
Publication of JP2007530675A5 publication Critical patent/JP2007530675A5/ja
Application granted granted Critical
Publication of JP4758984B2 publication Critical patent/JP4758984B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2007506135A 2004-03-29 2004-11-08 抗ｃｓ１抗体の治療的使用 Expired - Lifetime JP4758984B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US60/557,621 2004-03-29
US60/557,620 2004-03-29
US60/557,622 2004-03-29
US10/842,011 2004-05-07
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 2004-11-05
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
PCT/US2004/037430 WO2005102387A2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies

Publications (3)

Publication Number Publication Date
JP2007530675A JP2007530675A (ja) 2007-11-01
JP2007530675A5 JP2007530675A5 (enrdf_load_stackoverflow) 2009-01-08
JP4758984B2 true JP4758984B2 (ja) 2011-08-31

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506135A Expired - Lifetime JP4758984B2 (ja) 2004-03-29 2004-11-08 抗ｃｓ１抗体の治療的使用

Country Status (8)

Country Link
JP (1) JP4758984B2 (enrdf_load_stackoverflow)
CY (1) CY1115003T1 (enrdf_load_stackoverflow)
DK (1) DK2301576T3 (enrdf_load_stackoverflow)
ES (1) ES2393539T3 (enrdf_load_stackoverflow)
HR (1) HRP20120975T1 (enrdf_load_stackoverflow)
IL (1) IL243687A0 (enrdf_load_stackoverflow)
PT (1) PT2301576E (enrdf_load_stackoverflow)
SI (1) SI2301576T1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138282A1 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
FI3794042T3 (fi) 2018-05-18 2024-05-31 Daiichi Sankyo Co Ltd Anti-muc1-eksatekaani-vasta-aine-lääkekonjugaatti
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof

Also Published As

Publication number Publication date
HK1099699A1 (en) 2007-08-24
ES2393539T3 (es) 2012-12-26
IL243687A0 (en) 2016-04-21
HRP20120975T1 (hr) 2013-01-31
PT2301576E (pt) 2012-12-20
HK1155670A1 (en) 2012-05-25
CY1115003T1 (el) 2016-12-14
JP2007530675A (ja) 2007-11-01
SI2301576T1 (sl) 2013-02-28
DK2301576T3 (da) 2012-12-10

Similar Documents

Publication Publication Date Title
JP6042834B2 (ja) 抗ｃｓ１抗体の治療的使用
KR101146775B1 (ko) 항-ｃｓ1 항체의 치료적 용도
JP4758984B2 (ja) 抗ｃｓ１抗体の治療的使用
AU2015213401B9 (en) Therapeutic use of anti-CS1 antibodies
HK1242213A1 (en) Therapeutic use of anti-cs1 antibodies
HK1155670B (en) Therapeutic use of anti-cs1 antibodies
HK1163497B (en) Therapeutic use of anti-cs1 antibodies
HK1099699B (en) Therapeutic use of anti-cs1 antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090928

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110524

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110603

R150 Certificate of patent or registration of utility model

Ref document number: 4758984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140610

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term